Baroreflex Activation Therapy for Heart Failure
A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1090 participants.
Also called NCT02627196
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 1,090 participants
- Sponsor
- CVRx, Inc.
- Registry
-
NCT02627196
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT02627196. Randomized; no masking; primary purpose treatment. Start 2016-04-19 (actual); primary completion 2023-10 (actual). Results posted on 2026-03-10.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Baroreflex Activation Therapy for Heart Failure
- Acronym
- BeAT-HF
- Condition
- Heart Failure
- Intervention (Device)
- BAROSTIM NEO® System
- Intervention (Drug)
- Medical Management
- Lead sponsor
- CVRx, Inc.
Record details
- Record id
cardio:ct-nct02627196- Content hash
aa688c9202c718711242c2604ec6813e6a0276e64f2a1cecbddb39d873b6fe8c